Overview

Curosurf 120mg injection contains active components such as Poractant alfa. It is a lung surfactant medication used to treat Respiratory Distress Syndrome (RDS) in premature infants. It is a lifesaving medication that has improved the survival and outcomes of many premature infants. It has been shown to reduce the risk of death, the need for mechanical ventilation, and the length of hospital stay in premature infants with RDS. It is a good option for infants who are at risk for developing bronchopulmonary dysplasia (BPD), a chronic lung disease that can develop in premature infants. It is more stable than other surfactant medications, which means it can be stored longer without losing effectiveness.